Applied Therapeutics (NASDAQ:APLT) Upgraded by Wall Street Zen to "Sell" Rating

Wall Street Zen upgraded shares of Applied Therapeutics (NASDAQ:APLT - Free Report) to a sell rating in a research report sent to investors on Thursday.

Separately, Royal Bank of Canada reiterated a "sector perform" rating and issued a $1.50 price target on shares of Applied Therapeutics in a report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $6.10.

Applied Therapeutics Stock Performance

APLT stock traded down $0.00 on Thursday, reaching $0.41. The company had a trading volume of 1,900,676 shares, compared to its average volume of 3,364,237. Applied Therapeutics has a 1 year low of $0.30 and a 1 year high of $10.62. The company's fifty day moving average is $0.42 and its 200 day moving average is $1.60. The company has a market cap of $58.03 million, a P/E ratio of -0.25 and a beta of 2.00.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last posted its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). The company had revenue of $0.00 million during the quarter, compared to analysts' expectations of $0.61 million. On average, sell-side analysts predict that Applied Therapeutics will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP increased its holdings in shares of Applied Therapeutics by 904.4% during the 4th quarter. Vestal Point Capital LP now owns 11,500,000 shares of the company's stock worth $9,846,000 after buying an additional 10,355,000 shares during the last quarter. Propel Bio Management LLC increased its holdings in shares of Applied Therapeutics by 17.4% during the 1st quarter. Propel Bio Management LLC now owns 11,285,420 shares of the company's stock worth $5,517,000 after buying an additional 1,670,000 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Applied Therapeutics by 91.5% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 10,380,590 shares of the company's stock worth $5,076,000 after buying an additional 4,959,670 shares during the last quarter. VR Adviser LLC increased its holdings in shares of Applied Therapeutics by 1.7% during the 4th quarter. VR Adviser LLC now owns 9,990,591 shares of the company's stock worth $8,554,000 after buying an additional 165,591 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its holdings in shares of Applied Therapeutics by 2,458.3% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 8,762,291 shares of the company's stock worth $7,502,000 after buying an additional 8,419,781 shares during the last quarter. 98.31% of the stock is currently owned by institutional investors and hedge funds.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.